A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Inclusion Criteria:

• Ability and willingness to self-administer the study drug (or receive an injectionfrom a trained individual if visually impaired or with physical limitations)

• Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification orother locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratorytest at screening, and on stable oral therapy for at least 3 months prior toscreening (if applicable). T2DM may be treated with diet/exercise alone or any oralanti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.

• Body mass index (BMI) ≥27.0 kg/m^2

• History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight

Exclusion Criteria:

• History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosisor history of hyperosmolar state/coma within 12 months prior to screening

• Have had 1 or more episodes of severe hypoglycemia and/or has hypoglycemiaunawareness within the 6 months prior to screening

• At least 2 confirmed fasting blood glucose values >270 mg/dL (15.0 mmol/L) (on 2non-consecutive days) during screening

• Self-reported change in body weight >5 kg within 3 months prior to screening

• Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) ordiagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptordeficiency or Prader-Willi syndrome)

• Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty ifperformed more than 1 year prior to screening is allowed.

• Known clinically significant gastric emptying abnormality (e.g., severegastroparesis or gastric outlet obstruction)

• Poorly controlled hypertension at screening

• Have any of the following cardiovascular conditions within 3 months prior toscreening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transientischemic attack; Unstable angina; Hospitalization due to congestive heart failure

• Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptortriple agonist) within 6 months prior to randomization